CAJ | 학술논문

目的探讨胚胎干细胞因子性别决定区Y框蛋白2(Sox2)在小儿神经母细胞瘤组织中的表达及意义.方法应用免疫组化、RT-PCR、Realtime-PCR、免疫印迹等方法检测65例神经母细胞瘤和相应瘤旁组织中Sox2的表达,并分析其表达与临床病理参数的相关性.结果神经母细胞瘤组织中Sox2的表达水平明显高于瘤旁组织,两组间差异有统计学意义(P＜0.05)；Sox2在高分期肿瘤(Ⅲ～Ⅳ期)中的表达水平高于低分期肿瘤(Ⅰ～Ⅱ期),其mRNA相对表达量分别为0.0284±0.0087和0.0135±0.0075,差异有统计学意义(P＜0.05)；且未经化疗的肿瘤其Sox2的表达水平0.0284±0.0087高于经过化疗肿瘤的0.0076±0.0022,差异有统计学意义(P＜0.05).Sox2在神经母细胞瘤组织中的表达水平与患儿性别、年龄、肿瘤部位、大小、病理分型等参数无相关性(均P＞0.05).结论 Sox2在神经母细胞瘤中表达明显增高,且与其临床分期相关,提示Sox2可能参与神经母细胞瘤的发生和发展,化疗药物对其表达有抑制作用,其机制需值得进一步研究.
목적 탐토배태간세포인자성별결정구Y광단백2(Sox2)재소인신경모세포류조직중적표체급의의.방법 응용면역조화、RT-PCR、Realtime-PCR、면역인적등방법검측65례신경모세포류화상응류방조직중Sox2적표체,병분석기표체여림상병리삼수적상관성.결과 신경모세포류조직중Sox2적표체수평명현고우류방조직,량조간차이유통계학의의(P＜0.05)；Sox2재고분기종류(Ⅲ～Ⅳ기)중적표체수평고우저분기종류(Ⅰ～Ⅱ기),기mRNA상대표체량분별위0.0284±0.0087화0.0135±0.0075,차이유통계학의의(P＜0.05)；차미경화료적종류기Sox2적표체수평0.0284±0.0087고우경과화료종류적0.0076±0.0022,차이유통계학의의(P＜0.05).Sox2재신경모세포류조직중적표체수평여환인성별、년령、종류부위、대소、병리분형등삼수무상관성(균P＞0.05).결론 Sox2재신경모세포류중표체명현증고,차여기림상분기상관,제시Sox2가능삼여신경모세포류적발생화발전,화료약물대기표체유억제작용,기궤제수치득진일보연구.
Objective To investigate the expression and its clinical significance of Sox2 in neuroblastoma.Methods Sox2 expression in 65 samples of neuroblastoma tissues and paracancerous tissues was determined by immunohistochemical staining,Real-time PCR,and Western blot analysis.The relationship between the expression of Sox2 and clinical data was assessed.Results Sox2 mRNA relative expression level was significantly higher in tumor tissues than that in the adjacent noncancerous tissues (P＜0.05),and the relative expression levels of Sox2 in stage Ⅲ and Ⅳ NB were higher compared with those in stage Ⅰ and Ⅱ NB (P ＜0.05).Sox2 expression was significantly decreased in the chemotherapy subgroup as compared with that of the non-chemotherapy subgroup in stage Ⅲ and Ⅳ tumors (P＜0.05).Western blot analysis confirmed the results at the protein level.Sox2 expression was significantly correlated to the clinical stage of NB,but not other clinicopathological parameters including patient gender and age,tumor size,location and histological classification.Conclusions Sox2 is widely expressed in neuroblastoma and significantly correlated to the clinical stage.This suggests that the expression of Sox2 may correlate with the genesis and progression of neuroblastoma.Sox2 expression can be inhibited by chemotherapy which is worthy of further study.